Nature Medicine

In a phase 2 trial, the live-attenuated Chikungunya Vaccine (VLA1553) was given to children < 12y old in Honduras & the Dominican Republic, & was found to be safe & immunogenic.

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial | Nature Medicine Currently, no licensed vaccine is available against chikungunya virus (CHIKV) in children aged less than 12 years. In this phase 2, observer-blind,...

In the phase 1/2 TRIDENT-1 , treatment of patients with NRTK fusion–positive advanced solid tumors with repotrectinib led to systemic & intracranial clinical response. .

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial | Nature Medicine Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion–positive (NTRK+) solid tumors provide clinical benefit;...